27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
After the market close on June 27, MannKind (NASDAQ: MNKD) announced that it has received approval from the FDA for AFREZZA, an inhalation powder intended to improve glycemic control in adults with diabetes mellitus.
At last check, shares of MannKind hit a high of $12.50 in Monday's pre-market session after closing at $10 on Friday; shares have since pulled back to around $11.18.
"Approval of AFREZZA is an important milestone for MannKind, as today's FDA action validates the years of clinical research and commitment that powered the development of this unique therapy," said MannKind CEO Alfred Mann.
"We have seen in clinical studies that the combination of rapid action, injection-free delivery and ease of use makes AFREZZA a welcome alternative for many patients who require insulin," said Janet McGill, M.D., Professor of Medicine at Washington University School of Medicine.
Also included in the press release were the drug limitations of use, as well as a list of precautions and warnings
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!